BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple-negative breast cancer (TNBC) cells

Abstract

Repressing BET proteins’ function using bromodomain inhibitors (BETi) has been shown to elicit antitumor effects by regulating the transcription of genes downstream of BRD4. We previously showed that BETi promoted cell death of triple-negative breast cancer (TNBC) cells. Here, we proved that BETi induce altered mitochondrial dynamics fitness in TNBC cells falling in cell death. We demonstrated that BETi treatment downregulated the expression of BCL-2, and proteins involved in mitochondrial fission and increased fused mitochondria. Impaired mitochondrial fission affected oxidative phosphorylation (OXPHOS) inducing the expression of OXPHOS-related genes, SDHa and ATP5a, and increased cell death. Consistently, the amount of mitochondrial DNA and mitochondrial membrane potential (∆Ψm) increased in BETi-treated cells compared to control cells. Lastly, BETi in combination with Metformin reduced cell growth. Our results indicate that mitochondrial dynamics and OXPHOS metabolism support breast cancer proliferation and represent novel BETi downstream targets in TNBC cells.

References

[1] SiegelRL, MillerKD, FuchsHE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71:7-33.

[2] GuptaGK, Collier AL, LeeD, et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancer. 2020; 12:2392.

[3] JangMK, Mochizuki K, ZhouM, JeongHS, BradyJN, OzatoK. The Bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005; 19:523-534.

[4] RossiT, Zamponi R, ChiricoM, et al. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells. J Exp Clin Cancer Res. 2023; 42:7.

[5] AndrieuG, Belkina AC, DenisGV. Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today Technol. 2016; 19:45-50.

[6] ConeryAR, Centore RC, SpillaneKL, et al. Preclinical anticancer efficacy of BET bromodomain inhibitors is determined by the apoptotic response. Cancer Res. 2016; 76:1313-1319.

[7] MoldoveanuT, FollisAV, KriwackiRW, Green DR. Many players in BCL-2 family affairs. Trends Biochem Sci. 2014; 39:101-111.

[8] BholaPD, LetaiA. Mitochondria—judges and executioners of cell death sentences. Mol Cell. 2016; 61:695-704.

[9] WallaceDC. Mitochondrial diseases in man and mouse. Science. 1999; 283:1482-1488.

[10] Vander HeidenMG, Cantley LC, ThompsonCB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-1033.

[11] TangY, ZuckerRS. Mitochondrial involvement in post-tetanic potentiation of synaptic transmission. Neuron. 1997; 18:483-491.

[12] AhnCS, Metallo CM. Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 2015; 3:1.

[13] YouleRJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012; 337:1062-1065.

[14] ChenH, ChanDC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet. 2009; 18: R169-R176.

[15] WestermannB. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010; 11:872-884.

[16] Higuchi-SanabriaR, Charalel JK, VianaMP, et al. Mitochondrial anchorage and fusion contribute to mitochondrial inheritance and quality control in the budding yeast Saccharomyces cerevisiae. MBoC. 2016; 27:776-787.

[17] ChenH, ChomynA, ChanDC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem. 2005; 280:26185-26192.

[18] ChenH, Vermulst M, WangYE, et al. Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell. 2010; 141:280-289.

[19] Gallo CantafioME, Torcasio R, VigliettoG, AmodioN. Non-coding RNA-dependent regulation of mitochondrial dynamics in cancer pathophysiology. ncRNA. 2023; 9:16.

[20] GhoshP, VidalC, DeyS, ZhangL. Mitochondria targeting as an effective strategy for cancer therapy. Int J Mol Sci. 2020; 21:3363.

[21] YangG, ZhouD, LiJ, et al. VDAC1 is regulated by BRD4 and contributes to JQ1 resistance in breast cancer. Oncol Lett. 2019; 18:2340-2347.

[22] TanZ, ZhangX, KangT, Zhang L, ChenS. Arsenic sulfide amplifies JQ1 toxicity via mitochondrial pathway in gastric and colon cancer cells. Drug Des Devel Ther. 2018; 12:3913-3927.

[23] LiL, MengY, WuX, LiJ, SunY. Bromodomain-containing protein 4 inhibitor JQ1 promotes melanoma cell apoptosis by regulating mitochondrial dynamics. Cancer Sci. 2021; 112:4013-4025.

[24] TorcasioR, Gallo Cantafio ME, VenezianoC, et al. Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity. J Transl Med. 2024; 22:208.

[25] RoccaC, SodaT, de FrancescoEM, et al. Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer. J Transl Med. 2023; 21:635.

[26] VitalitiA, Roccatani I, IorioE, et al. AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism. Cell Oncol. 2023; 46:93-115.

[27] ColemanDJ, GaoL, SchwartzmanJ, et al. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. Sci Rep. 2019; 9:3823.

[28] MaesME, Grosser JA, FehrmanRL, SchlampCL, Nickells RW. Completion of BAX recruitment correlates with mitochondrial fission during apoptosis. Sci Rep. 2019; 9:16565.

[29] FairlieWD, LeeEF. Co-Operativity between MYC and BCL-2 pro-survival proteins in cancer. Int J Mol Sci. 2021; 22:2841.

[30] JovanovićB, Temko D, StevensLE, et al. Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell Rep. 2023; 42:113564.

[31] RaiY, PathakR, KumariN, et al. Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. Sci Rep. 2018; 8:1531.

[32] ConradM, KaganVE, BayirH, et al. Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev. 2018; 32:602-619.

[33] VyasS, Zaganjor E, HaigisMC. Mitochondria and cancer. Cell. 2016; 166:555-566.

[34] Sarmiento-SalinasFL, Delgado-Magallón A, Montes-AlvaradoJB, et al. Breast cancer subtypes present a differential production of reactive oxygen species (ROS) and susceptibility to antioxidant treatment. Front Oncol. 2019; 9:480.

[35] HuC, HuangY, LiL. Drp1-dependent mitochondrial fission plays critical roles in physiological and pathological progresses in mammals. Int J Mol Sci. 2017; 18:144.

[36] GenoveseI, Carinci M, ModestiL, AguiariG, PintonP, GiorgiC. Mitochondria: insights into crucial features to overcome cancer Chemoresistance. Int J Mol Sci. 2021; 22:4770.

[37] PetrellaG, Ciufolini G, VagoR, CiceroDO. The interplay between oxidative phosphorylation and glycolysis as a potential marker of bladder cancer progression. Int J Mol Sci. 2020; 21:8107.

[38] KennedyL, SandhuJK, HarperM-E, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020; 10:1429.

[39] RamamoorthyH, Abraham P, IsaacB. Mitochondrial dysfunction and electron transport chain complex defect in a rat model of tenofovir disoproxil fumarate Nephrotoxicity: mitochondrial dysfunction in tenofovir nephrotoxicity. J Biochem Mol Toxicol. 2014; 28:246-255.

[40] ZorovaLD, PopkovVA, PlotnikovEY, et al. Mitochondrial membrane potential. Anal Biochem. 2018; 552:50-59.

[41] JanzerA, GermanNJ, Gonzalez-HerreraKN, AsaraJM, HaigisMC, StruhlK. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci USA. 2014; 111:10574-10579.

[42] LiuX, RomeroIL, LitchfieldLM, LengyelE, Locasale JW. Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab. 2016; 24:728-739.

[43] AlfarasI, Mitchell SJ, MoraH, et al. Health benefits of late-onset metformin treatment every other week in mice. NPJ Aging Mech Dis. 2017; 3:16.

[44] BerthonC, Raffoux E, ThomasX, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016; 3: e186-e195.

[45] AmorimS, Stathis A, GleesonM, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016; 3: e196-e204.

[46] StathisA, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018; 8:24-36.

[47] da MottaLL, LedakiI, PurshouseK, et al. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene. 2017; 36:122-132.

[48] BevillSM, Olivares-Quintero JF, SciakyN, et al. GSK2801, a BAZ2/BRD9 Bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Mol Cancer Res. 2019; 17:1503-1518.

[49] WallaceDC. Mitochondria and cancer. Nat Rev Cancer. 2012; 12:685-698.

[50] RothKG, Mambetsariev I, KulkarniP, SalgiaR. The mitochondrion as an emerging therapeutic target in cancer. Trends Mol Med. 2020; 26:119-134.

[51] GiacomelloM, Pyakurel A, GlytsouC, ScorranoL. The cell biology of mitochondrial membrane dynamics. Nat Rev Mol Cell Biol. 2020; 21:204-224.

[52] PavlovaNN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016; 23:27-47.

[53] LuengoA, GuiDY, Vander HeidenMG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017; 24:1161-1180.

[54] DeBerardinisRJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016; 2:e1600200.

[55] RedaA, RefaatA, Abd-RabouAA, et al. Role of mitochondria in rescuing glycolytically inhibited subpopulation of triple negative but not hormone-responsive breast cancer cells. Sci Rep. 2019; 9:13748.

[56] LanningNJ, CastleJP, SinghSJ, et al. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities. Cancer Metab. 2017; 5:6.

[57] LeBleuVS, O’Connell JT, Gonzalez HerreraKN, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014; 16:992-1003.

[58] YaoC-H, WangR, WangY, Kung CP, WeberJD, PattiGJ. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. Elife. 2019; 8:e41351.

[59] LiC-J, TzengYDT, ChiuYH, Lin HY, HouMF, ChuPY. Pathogenesis and potential therapeutic targets for triple-negative breast cancer. Cancer. 2021; 13:2978.

[60] AndrikopoulouA, Liontos M, KoutsoukosK, DimopoulosM-A, Zagouri F. The emerging role of BET inhibitors in breast cancer. Breast. 2020; 53:152-163.

[61] WangZ-Q, ZhangZC, WuYY, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Sig Transduct Target Ther. 2023; 8:420.

[62] ZhangY, XuB, ShiJ, et al. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways. Cell Oncol. 2020; 43:1049-1066.

[63] SunF, HuoX, ZhaiY, et al. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell. 2005; 121:1043-1057.

[64] CecchiniG. Function and structure of complex II of the respiratory chain. Annu Rev Biochem. 2003; 72:77-109.

[65] KluckovaK, Bezawork-Geleta A, RohlenaJ, DongL, NeuzilJ. Mitochondrial complex II, a novel target for anti-cancer agents. Biochim Biophys Acta—Bioenergetics. 2013; 1827:552-564.

[66] CardaciS, ZhengL, MacKayG, et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol. 2015; 17:1317-1326.

[67] Lussey-LepoutreC, Hollinshead KER, LudwigC, et al. Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun. 2015; 6:8784.

[68] CivenniG, Bosotti R, TimpanaroA, et al. Epigenetic control of mitochondrial fission enables self-renewal of stem-like tumor cells in human prostate cancer. Cell Metab. 2019; 30:303-318.e6.

[69] SeoJH, Agarwal E, ChaeYC, et al. Mitochondrial fission factor is a novel Myc-dependent regulator of mitochondrial permeability in cancer. EBioMedicine. 2019; 48:353-363.

[70] KochB, TravenA. Mdivi-1 and mitochondrial fission: recent insights from fungal pathogens. Curr Genet. 2019; 65:837-845.

[71] AnisimovVN. Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget. 2015; 6:39398-39407.

[72] ChenC, WangH, GengX, et al. Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway. Cancer Cell Int. 2021; 21:404.

[73] JingY, ZhangZ, MaP, et al. Concomitant BET and MAPK blockade for effective treatment of ovarian cancer. Oncotarget. 2016; 7:2545-2554.

[74] GopalakrishnanR, MattaH, TolaniB, Triche T Jr, ChaudharyPM. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016; 35:1797-1810.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.